The improvements in stent flexibility and biocompatibility have lead to the conclusion by Dr. Mitchell Krucoff that second-generation drug eluting-stents, such as Abbott's Xience stent, result in an improved ability to prevent restenosis following angioplasty and stent implantation. See an excerpt from India's pharmabiz.com (which also highlights the market potential for coronary stents in India): [...]
The shape of various coronary stents can vary widely from one manufacturer to another. The five main categorical shapes of coronary stents are tubular, coil, ring, mesh and multi-design. Balloon-expanded stents are typically of stainless steel construction while shape-memory alloys are typically self-expanding. Because of the nature of their use, stents should ideally be very [...]
Drug-eluting stents were developed to release a drug (e.g., sirolimus or paclitaxel) intended to reduce the incidence of restenosis. From there, even more innovative products have been developed, such as bioactive stents or stents designed to attract a patient’s own endothelial cells to coat the stent (as in devices by OrbusNeich, Hexacath, and Miami Cardiovascular [...]
The worldwide market for drug-eluting, as well as bare, bioresorbable and other stents, is now the subject of the May 2009 report by MedMarket Diligence, Report #C245. Below is an excerpt from MedMarket Diligence’s coverage of the drug-eluting stents market in mid-2008. The previous scarcity of long term data left some uncertainty about DES’ clinical and [...]
Coronary stents represent a worldwide market in the $billions due to their potential to address coronary artery disease without the invasive sternotomy, while demonstrating outcomes that rival coronary artery bypass graft procedures, particularly for advanced drug-eluting coronary stents. Given the financial stakes in the coronary stent market, it has driven the proliferation of competitors seeking [...]
[Through the course of researching and analyzing coronary artery disease treatments, technologies and markets for our May 2009 worldwide coronary stents market report, we have compiled data on the ancillary market of drug-eluting balloons, which we synopsize below.] Drug-Eluting Balloons A handful of companies are developing drug-coated balloon catheters as an alternative to balloon angioplasty and [...]
Contact:
